Diagnosing central precocious puberty in young girls often requires subjecting children to multiple blood tests. Researchers say they discovered a simpler, less invasive way to make the diagnosis.
Researchers presented a secondary analysis of data from a phase 3 trial evaluating 6-month subcutaneous leuprolide acetate 45 mg therapy for central precocious puberty.
Pathological brain lesions are not common on MRI in girls with central precocious puberty in the absence of signs or symptoms of CNS lesions.
The FDA has approved Fensolvi (leuprolide acetate; Tolmar Pharmaceuticals) for the treatment of pediatric patients 2 years of age and older with central precocious puberty.
The association between precocious puberty and a wide range of preexisting medical conditions could provide additional insight into factors contributing to early pubertal onset.
Among girls with true central precocious puberty referred to a tertiary center in Israel, nonclassical congenital adrenal hyperplasia was diagnosed in almost 5% of patients.
Gonadotropin-releasing hormone (GnRH) agonist Triptodur treats central precocious puberty via intramuscular injection.
Data from a phase 3 clinical trial found that triptorelin achieved positive results in patients age 2 and older with central precocious puberty.
Ovarian cyst and McCune-Albright syndrome were most responsible for the increased risk of non-congenital adrenal hyperplasia gonadotropin-independent precocious puberty.
Long-term treatment with the histrelin implant safely and effectively sustained gonadotropin suppression and improved predicted adult height in central precocious puberty.
